Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFenner PLC Regulatory News (FENR)

  • There is currently no data for FENR

Pre-Close Trading Statement

12 Mar 2015 07:00

RNS Number : 2234H
Fenner PLC
12 March 2015
 

12 March 2015

 

Fenner PLC

("Fenner" or "the Group")

 

Pre-Close Trading Statement

 

Trading in the period

The Group's trading in the first half of its financial year ended 28 February 2015 continued to be characterised by a good performance by the AEP Division and challenging market conditions for the ECS Division. As a consequence, AEP is now contributing more than one-half of the Group's operating profit1.

Considerable emphasis is being placed across the Group on cost reduction. There are ongoing programmes in both ECS and AEP to manage variable costs. In addition, the Group can confirm that it has now completed the necessary actions to deliver the annualised reduction in cash overhead expenditure of £9 million announced in the AGM Trading Statement. As previously advised, there will be an exceptional charge in the first half of the year to reflect the expenses incurred in achieving these cost reductions.

Trading in the AEP Division has continued to be in line with expectations and the Division finished the first half of the year well. The Group's medical activities were expanded by the acquisition of Charter Medical, which augments the technology platform of Solesis and continues the strategy of developing our medical business both organically and by acquisition.

In ECS, the results of our Americas and EMEA businesses in the period remained in line with expectations. Whilst our market position in Australia remains strong, results were below expectations as continuing price pressure was exacerbated by lower activity levels.

Balance sheet

The Group's balance sheet remains strong. Borrowings at 28 February 2015 were in line with expectations and, as a result of our focus on cash management, reflected better than usual seasonal movements in working capital, offset by exchange rate variations and the acquisition of Charter Medical for £19 million.

Outlook

The non-oil specialty polymer businesses in AEP, which represent approximately two-thirds of divisional turnover, are expected to continue to perform well. The acquisition of Charter Medical is expected to provide a small positive impact on the Group's earnings for the year as a whole.

As previously anticipated, in response to the continuing lower oil price, order intake in AEP's businesses which serve the oil & gas industry has recently fallen quite sharply. We continue to implement further cost reductions whilst preserving the businesses' strategic strengths and their flexibility to respond to any recovery in their markets.

In ECS, we expect a continuation of the difficult trading conditions seen in the first half, although the results will benefit from the reduced cost base. The Division is well invested and requires only limited capital expenditure in the near future. Consequently, the business is being managed so as to generate good cash flow whilst ensuring a cost base appropriate to the demand level.

As a consequence of the above, the Group anticipates achieving underlying earnings per share for the year moderately below expectations.

Reporting timetable

The Group expects to release its Half-yearly Report on 22 April 2015.

Before amortisation of intangible assets acquired and exceptional items

-Ends-

 

Analyst and Investor conference call

A conference call for analysts and investors will be held at 8:30 a.m. (UK time) today to discuss this statement. Participants can join the call on + 44 (0)20 3059 8125. A recording of this conference call will be available for 7 days on + 44 (0)12 1260 4861 using the access code 0451922 followed by #.

For further information please contact:

Fenner PLC

Nicholas Hobson, Chief Executive OfficerJohn Pratt, Group Finance Director

01482 626501

Weber Shandwick Financial

Nick Oborne / Tom Jenkins

020 7067 0700

Notes to editors:

Fenner PLC is a world leader in reinforced polymer technology, providing local engineered solutions for performance-critical applications. The Group operates through two divisions:

Engineered Conveyor Solutions: the ECS division, trading under the Fenner Dunlop, Fenner and Dunlop brand names, is a recognised leader in the global conveying market. The division offers a unique, comprehensive suite of products and services, which serve the conveying needs of mining, power generation and bulk handling markets.

Advanced Engineered Products: the AEP division uses advanced polymeric materials and technical expertise to provide high value-added solutions to customers' most challenging engineering problems. Customers are spread across a variety of end-user segments, including oil & gas and medical which account for some 40 per cent of divisional revenue, together with construction, transportation, automation and general industrial. AEP's trading names are recognised globally and include CDI Energy Products, EGC Critical Components, Hallite, AIP Precision Machining, Fenner Precision, Fenner Drives, James Dawson, Mandals, Secant Medical, Charter Medical and Xeridiem.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGMGMFLMLGKZM
Date   Source Headline
19th Aug 20147:00 amRNSDirectorate Change
6th Aug 20142:13 pmRNSDirector/PDMR Shareholding
6th Aug 201410:33 amRNSDirector/PDMR Shareholding
16th Jul 20147:00 amRNSInterim Management Statement
30th Jun 20143:06 pmRNSHolding(s) in Company
20th Jun 201412:40 pmRNSHolding(s) in Company
12th Jun 20147:00 amRNSCapital Markets Event
6th Jun 201411:20 amRNSDirector/PDMR Shareholding
5th Jun 20141:43 pmRNSDirector/PDMR Shareholding
30th May 20147:00 amRNSTrading Update
24th Apr 20144:10 pmRNSHolding(s) in Company
23rd Apr 20147:00 amRNSHalf Yearly Report
15th Apr 201412:17 pmRNSHolding(s) in Company
2nd Apr 20142:02 pmRNSHolding(s) in Company
13th Mar 20149:34 amRNSHolding(s) in Company
11th Mar 20147:00 amRNSPre-Close Trading Statement
5th Mar 20143:47 pmRNSHolding(s) in Company
3rd Mar 201410:49 amRNSBlocklisting Interim Review
20th Feb 20142:47 pmRNSHolding(s) in Company
4th Feb 20149:59 amRNSDirector/PDMR Shareholding
31st Jan 201412:28 pmRNSHolding(s) in Company
24th Jan 20142:40 pmRNSHolding(s) in Company
23rd Jan 201412:21 pmRNSHolding(s) in Company
17th Jan 20141:36 pmRNSResult of AGM
15th Jan 20147:00 amRNSInterim Management Statement
12th Dec 201310:49 amRNSDocuments Available for Inspection/Notice of AGM
29th Nov 20139:24 amRNSTotal Voting Rights
25th Nov 20139:16 amRNSDirector/PDMR Shareholding
21st Nov 20133:39 pmRNSDirector/PDMR Shareholding
14th Nov 201311:27 amRNSAdditional Listing
13th Nov 201310:15 amRNSAmendment
13th Nov 20137:00 amRNSFinal Results
8th Nov 20132:25 pmRNSHolding(s) in Company
21st Oct 20132:35 pmRNSHolding(s) in Company
27th Sep 20132:38 pmRNSHolding(s) in Company
10th Sep 20137:00 amRNSPre-close Trading Statement
2nd Sep 20132:01 pmRNSBlocklisting Interim Review
28th Aug 201311:35 amRNSHolding(s) in Company
22nd Aug 201312:16 pmRNSHolding(s) in Company
7th Aug 20134:35 pmRNSHolding(s) in Company
31st Jul 201312:38 pmRNSHolding(s) in Company
18th Jul 20137:00 amRNSInterim Management Statement
10th Jul 20139:21 amRNSHolding(s) in Company
9th Jul 20132:10 pmRNSHolding(s) in Company
5th Jul 20133:14 pmRNSHolding(s) in Company
21st Jun 201310:05 amRNSDirector/PDMR Shareholding
10th Jun 201310:50 amRNSDirector/PDMR Shareholding
5th Jun 201310:55 amRNSDirector/PDMR Shareholding
30th May 20132:33 pmRNSDirector/PDMR Shareholding
24th May 20133:46 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.